Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX – Get Rating) saw a large drop in short interest during the month of April. As of April 30th, there was short interest totalling 5,500 shares, a drop of 41.5% from the April 15th total of 9,400 shares. Based on an average daily volume of 32,500 shares, the days-to-cover ratio is currently 0.2 days.

Evaxion Biotech A/S stock traded up $0.01 during midday trading on Friday, hitting $1.74. 92,745 shares of the stock were exchanged, compared to its average volume of 1,125,158. The company has a fifty day simple moving average of $2.84 and a two-hundred day simple moving average of $3.82. Evaxion Biotech A/S has a 52 week low of $1.51 and a 52 week high of $25.04. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.10.

Evaxion Biotech A/S (NASDAQ:EVAX – Get Rating) last released its quarterly earnings data on Wednesday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.08. During the same quarter in the prior year, the business posted ($0.23) EPS. As a group, sell-side analysts anticipate that Evaxion Biotech A/S will post -1.64 EPS for the current year.

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Credit Suisse AG bought a new position in shares of Evaxion Biotech A/S (NASDAQ:EVAX – Get Rating) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 40,315 shares of the company’s stock, valued at approximately $389,000. Credit Suisse AG owned 0.21% of Evaxion Biotech A/S as of its most recent filing with the SEC. 4.65% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research raised shares of Evaxion Biotech A/S from a “sell” rating to a “hold” rating in a research note on Thursday.

About Evaxion Biotech A/S (Get Rating)

Evaxion Biotech A/S, an artificial intelligence (AI)-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform.

Read More